Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$103.14 USD

103.14
4,986,452

+0.18 (0.17%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $103.11 -0.03 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Ecolab (ECL) Q3 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across all segments drives its third-quarter sales despite business challenges.

Zacks Equity Research

Avantor (AVTR) Q3 Earnings In-Line With Estimates, Revenues Top

by Zacks Equity Research

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft third-quarter performance.

Zacks Equity Research

Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View

by Zacks Equity Research

Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.

Zacks Equity Research

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

Zacks Equity Research

Integer Holdings (ITGR) Q3 Earnings Top Estimates, FY23 View Up

by Zacks Equity Research

Integer Holdings' (ITGR) third-quarter results reflect robust Medical Sales, along with strength in the majority of the product lines.

Zacks Equity Research

Merit Medical (MMSI) Q3 Earnings Top Estimates, FY23 View Revised

by Zacks Equity Research

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the third quarter.

Zacks Equity Research

Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips

by Zacks Equity Research

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter.

Zacks Equity Research

Compared to Estimates, Boston Scientific (BSX) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Boston Scientific (BSX) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 4.17% and 1.77%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NextGen (NXGN) Q2 Earnings Top Estimates, Margins Down

by Zacks Equity Research

NextGen's (NXGN) second-quarter fiscal 2024 results reflect strength in its Recurring revenues.

Urmimala Biswas headshot

Medical Device Stocks' Q3 Earnings Due on Oct 26: BSX, BIO & More

by Urmimala Biswas

Medical Device companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, BIO, EW and LH fare this time.

Zacks Equity Research

Shockwave Medical (SWAV) Announces IVL Studies' Positive Results

by Zacks Equity Research

Shockwave Medical's (SWAV) latest announcement of two new publications validates the utility of IVL in complex nodular and eccentric calcium.

Zacks Equity Research

What's in Store for Boston Scientific (BSX) in Q3 Earnings?

by Zacks Equity Research

With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improved further in the third quarter.

Zacks Equity Research

The Zacks Analyst Blog Highlights Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific

by Zacks Equity Research

Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Visa, AbbVie & BHP

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and BHP Group Limited (BHP).

Zacks Equity Research

Boston Scientific's (BSX) Wavewriter Alpha SCS Gets FDA's Nod

by Zacks Equity Research

Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems.

Zacks Equity Research

QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-respiratory product sales.

Zacks Equity Research

Walgreens Boots (WBA) Q4 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Walgreens Boots (WBA) Q4 retail revenues are impacted by macroeconomic-driven consumer pressure and lower COVID-19 OTC test kit sales.

Zacks Equity Research

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.

Indrajit Bandyopadhyay headshot

5 Medical Product Stocks to Buy Amid Industry Recovery

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.

Zacks Equity Research

Neogen's (NEOG) Q1 Earnings Miss Estimates, Margins Rise

by Zacks Equity Research

Neogen's (NEOG) Q1 Animal Safety business experiences continued destocking, with channel inventory levels reaching multi-year lows.

Zacks Equity Research

Here's Why You Should Invest in Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on consistent growth and upbeat guidance.

Zacks Equity Research

AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.

Zacks Equity Research

PBH or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PBH vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts

by Zacks Equity Research

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.